Inside UAE-PRIME: How Abu Dhabi Became a Testing Ground for Elon Musk's Brain Chip

When Neuralink needed a site for its first clinical trial outside North America, it didn't pick London, Tokyo, or Singapore. It picked Abu Dhabi.

In May 2025, Elon Musk's brain-computer interface (BCI) company announced UAE-PRIME, a study run jointly with Cleveland Clinic Abu Dhabi and the Abu Dhabi Department of Health (DoH). It was, as DoH chairman Mansoor Al Mansoori put it at the time, Neuralink's first international site, and the first BCI study of its kind in the Middle East, according to coverage in Khaleej Times and Gulf News. Nearly a year and a half later, it's worth unpacking what the trial is actually testing, how the underlying technology works, and why a country of under 10 million people landed one of the most closely watched experiments in neurotechnology.

What UAE-PRIME is actually testing

UAE-PRIME is not a treatment — it's a feasibility study. Its registry entry on ClinicalTrials.gov (NCT06992596) lists it as recruiting, with an estimated enrollment of around ten participants, a start date of May 9, 2025, and a planned run through November 2027.

The inclusion criteria are specific: adults with a spinal cord injury or stroke that happened more than 12 months earlier, causing motor impairment in both arms with no realistic prospect of recovery. In other words, people for whom existing rehabilitation has plateaued, and who can't reliably use their hands to operate a keyboard, mouse, or phone.

Participants undergo a short procedure in which Neuralink's R1 surgical robot implants the N1 device into a region of the brain's motor cortex associated with the intention to move. The chip itself is wireless and rechargeable, sitting flush with the skull, with roughly a thousand ultra-thin electrode threads threading into the brain tissue beneath it. Those threads pick up the electrical firing patterns of individual neurons.

The study design runs an 18-month primary phase focused on safety and whether the device reliably picks up those signals, inside a roughly six-year follow-up window — standard for an implanted medical device trial, where regulators want years of data before anyone calls it safe for routine use.

How the chip turns a thought into a cursor click

The part that sounds like science fiction is actually a fairly mechanical signal-processing problem. When you intend to move your hand, your motor cortex fires a specific, somewhat repeatable pattern of electrical spikes, whether or not the hand itself can actually move. Neuralink's N1 is essentially a very dense, very small recording array that listens to that firing pattern through its implanted threads.

The raw data is noisy, so the chip doesn't try to "read thoughts" in any general sense. It's trained, per patient, to recognize the specific spike patterns that correspond to a handful of intended movements, say, moving a cursor left, right, up, down, or clicking. A machine-learning model on the device (and in supporting software) is calibrated during onboarding sessions, where the participant repeatedly tries to make a movement while the system learns to associate the neural pattern with the intended action.

Over time, in Neuralink's earlier US trials, participants have used this setup to move a computer cursor, play chess and simple video games, and operate software entirely through intention, no hands, no eye tracking, no voice. UAE-PRIME is testing whether the same device and the same approach can be delivered as safely and effectively through a different hospital system, a different surgical team, and a different regulatory environment.

Why Abu Dhabi

Two tracks were converging. Cleveland Clinic Abu Dhabi, opened in 2015 as the Ohio-based hospital system's first and largest location outside the US, gave Neuralink a facility with neurosurgical infrastructure already built to American accreditation standards, which matters enormously for a device trial that has to satisfy regulators on both sides of the relationship.

The Abu Dhabi Department of Health, meanwhile, has spent the past several years positioning the emirate as a place where advanced-therapy and medtech trials can move faster than in more heavily bureaucratized markets, part of a broader UAE push to become a hub for applied AI and biotech, alongside efforts like the Mohamed bin Zayed University of Artificial Intelligence and the state-backed AI group G42. That overlap is not incidental: G42 was reported among the backers of Neuralink's roughly $650 million Series E funding round in 2025, giving Abu Dhabi a financial stake in the company's success as well as a clinical one.

There's a second, less publicized UAE-linked effort worth noting. Separately from UAE-PRIME, a company developing a device called Blindsight, aimed at restoring a form of vision via direct brain stimulation rather than the eyes, has also been reported to be working toward a human implant with Cleveland Clinic Abu Dhabi as a partner site. It's a distinct device and a distinct trial, but it reinforces the pattern: Abu Dhabi's hospital infrastructure has become a preferred testing ground for a category of neurotech that's still largely unapproved anywhere in the world.

What to actually watch for

Because UAE-PRIME is a feasibility study, the near-term milestone isn't "patient controls a robot arm with their mind", it's a quieter one: has the first participant in Abu Dhabi been safely implanted, and is the device recording usable signal. As of the trial's most recent public registry update, no implant date had been publicly confirmed by Neuralink or Cleveland Clinic Abu Dhabi.

That's worth sitting with. Brain-computer interfaces generate outsized hype relative to how early the science still is: as of Neuralink's own public updates, the company has implanted the N1 in a small number of patients globally, and the field broadly, including competitors like Synchron and Precision Neuroscience, is still in early safety trials rather than approved products. UAE-PRIME matters not because it proves the technology works, but because it's the clearest sign yet that the next phase of BCI testing is going to be genuinely international, and that Abu Dhabi has deliberately positioned itself to be part of it.